VITAGLUCIDE (Tirzepatide Injection)
The Dual-Action Powerhouse for Diabetes and Weight Management
Contents:
Tirzepatide 5mg Vials (for SC/IM Administration) × 5
Sterile Water for Injection (2ml Ampoules) × 5
What is VITAGLUCIDE?
VITAGLUCIDE is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, engineered to mimic the body's natural incretin hormones. It offers superior glycemic control and sustained weight loss by targeting multiple metabolic pathways:
- Enhances insulin secretion in a glucose-dependent manner.
- Suppresses glucagon secretion, reducing liver glucose production.
- Slows gastric emptying, promoting satiety and reducing caloric intake.
- Curbs appetite via central nervous system effects.
Additional Cardiovascular Benefits:
VITAGLUCIDE has demonstrated efficacy in reducing the risk of major adverse cardiovascular events (MACE), including stroke, heart attack, and cardiovascular mortality in adults with type 2 diabetes and established heart disease.
How VITAGLUCIDE Helps
1. Blood Sugar Control
Optimizes postprandial and fasting glucose levels in type 2 diabetes.
Reduces HbA1c significantly, even in refractory cases.
2. Weight Management
Promotes clinically significant weight loss (up to 15% of body weight in trials).
Sustains long-term reduction in visceral fat and BMI.
3. Cardiovascular Protection
Lowers systemic inflammation and improves endothelial function.
Reduces atherosclerotic risks in high-risk patients.
Administration & Storage
Route of Administration:
Subcutaneous (SC) or Intramuscular (IM) injection.
Storage Guidelines:
- Before Reconstitution: Store at room temperature (≤25°C), protected from heat and light.
- After Reconstitution: Refrigerate at 2-8°C; use within 7 days.
- Do not freeze or expose to direct sunlight.
Dosage Protocol
Recommended Titration Schedule:
- Initial Dose: 2.5mg once weekly (4 weeks for acclimatization).
- Maintenance Dose: Escalate to 5mg/week, then 10mg or 15mg/week as tolerated.
Key Considerations:
- Gradual escalation minimizes GI side effects (e.g., nausea, vomiting).
- Individualized titration based on glycemic response, weight loss goals, and tolerability.
- Medical supervision mandatory for dose adjustments beyond 10mg/week.
Comparison: GLYCOTIDE (Semaglutide) vs. VITAGLUCIDE (Tirzepatide)
GLYCOTIDE (Semaglutide) is a well-established GLP-1 receptor agonist known for its effective blood sugar regulation and steady weight loss benefits. It works by enhancing insulin secretion, slowing digestion, and reducing appetite, making it a reliable choice for long-term metabolic management. Its safety profile is thoroughly documented, and it is often preferred for patients who require gentler, sustained effects with a lower risk of digestive discomfort.
VITAGLUCIDE (Tirzepatide), on the other hand, represents the next generation of metabolic therapy with its dual GIP and GLP-1 receptor activation. This dual mechanism delivers more aggressive glucose control and faster, more significant weight loss compared to GLP-1-only medications. While it shares similar gastrointestinal side effects, its enhanced potency may lead to quicker visible results, though it can also be slightly less tolerable at higher doses for some individuals.
Which one is right for you?
- Choose GLYCOTIDE for proven, steady results with a milder adjustment period.
- Opt for VITAGLUCIDE if you seek maximum metabolic impact and are comfortable with closer medical supervision during dose escalation.
Contraindications
Avoid VITAGLUCIDE if:
- Personal/family history of medullary thyroid carcinoma (MTC).
- Diagnosis of Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Hypersensitivity to tirzepatide or excipients.
Special Precautions
-
Thyroid C-Cell Tumor Risk
Animal studies showed dose-dependent thyroid tumors; human relevance unknown.
Monitor for neck masses/dysphagia in high-risk patients. -
Pancreatitis
Discontinue if severe, persistent abdominal pain occurs. -
Renal Impairment
Dehydration from GI side effects may precipitate acute kidney injury.
Monitor creatinine/eGFR in CKD patients. -
Diabetic Retinopathy
Rapid glucose lowering may temporarily worsen retinopathy; monitor ophthalmologically. -
Pregnancy & Lactation
Not recommended due to insufficient safety data.
The Revolutionary TEMPORECT PRO™ Packaging
Denik Pharm's cutting-edge peptide packaging ensures optimal stability:
- Temperature & Shock Proof: Protects from heat, UV light, and physical stress during transit.
- Preserves Potency: Rigorously tested to maintain 100% peptide integrity.
- Leak-Proof Design: Prevents contamination post-reconstitution.
Why Choose VITAGLUCIDE?
✅ Dual-action efficacy (GIP + GLP-1) for superior metabolic outcomes.
✅ Proven weight loss and cardiovascular benefits.
✅ Flexible dosing with minimal rebound effects.
✅ Industry-leading TEMPORECT PRO™ stability assurance.
For adults with type 2 diabetes or obesity—VITAGLUCIDE redefines treatment.
Disclaimer
- Product images are representational; actual packaging may vary.
- Consult a healthcare provider before use—not for self-administration without supervision.
- Store as directed to prevent efficacy loss.
